

# SunEdison Inc.

## Disclosing a Tough Outlook

### On Christmas Eve SUNE gives present of enhanced disclosures

Mgmt provided a full view of 2016 liquidity seemingly as part of a disclosure resulting from its ongoing financing efforts (began 12/10) for a \$650 Mn credit facility. While some appear to be viewing disclosures as encouraging of a 'bridge' to improvement, we alternatively view the disclosures as reiterating concerns on immediate cash liquidity heading into 1Q, and further focus on SUNE assumptions of margin achievable at its DevCo and services businesses. Beyond liquidity as SUNE continues to finance the business primarily with debt (as evidenced by the latest issuance) we simply see limited equity value given the magnitude of obligations.

### Financing terms are next key datapoint: at what price can it happen?

With the contemplated \$650 Mn second-lien credit financing likely refinancing the \$169 Mn GS term-loan (due in August at an all-in effective rate of ~15%), we see this as the next key datapoint for shares. Ability to raise debt capital on palatable terms (eg-without increasing its cash interest expense) would appear a positive, particularly with the facility extending incremental liquidity. Every dollar counts in this environment. Risk to shares relates primarily to closing terms incl. any associated equity raise/warrants.

### Services business is the new focus for 'core' of company; define 'service' first

Mgmt appears quite focused in articulating the value proposition of its services biz in 2016, disclosing a projected \$223Mn in EBITDA in 2016. If achievable we estimate this would imply ~\$7/sh in value to shares. However, looking through to comps and past guidance we believe execution at these implied margins could be unsustainable (rev at implied at ~\$60/kW-yr vs. UBSe rev of \$20/kW-yr) and margins of ~\$30/kW-yr vs. our est of ~\$4/kW-yr. Mgmt includes PPA revenue in its services segment which seemingly overstates the pure-play O&M services biz.

### Valuation: Maintain Sell-rating as debt continues to grow

We remain cautious on shares. While they've recovered appreciably in recent weeks as solar ITC extension has lifted the whole sector we see risk in the 2016 guidance. Disclosures only reiterate our funding concerns and granularity on assumptions embedded in '16 FCF has clear downside risk in our view.

### Equities

Americas  
Electric Components & Equipment

12-month rating **Sell**

12m price target **US\$2.00**

Price **US\$5.92**

RIC: SUNE.N BBG: SUNE US

### Trading data and key metrics

52-wk range	US\$32.13-2.82
Market cap.	US\$1.61bn
Shares o/s	272m (COM)
Free float	99%
Avg. daily volume ('000)	7,865
Avg. daily value (m)	US\$43.7
Common s/h equity (12/15E)	US\$1.28bn
P/BV (12/15E)	1.4x
Net debt / EBITDA (12/15E)	0.5x

### EPS (UBS, diluted) (US\$)

	12/15E	
	UBS	Cons.
Q1	(0.76)	(1.36)
Q2	(0.88)	(0.93)
Q3E	(0.84)	(0.91)
Q4E	0.71	(0.67)
12/15E	(1.72)	(3.66)
12/16E	(0.53)	(1.86)
12/17E	(0.33)	(1.62)

### Julien Dumoulin-Smith

Analyst  
julien.dumoulin-smith@ubs.com  
+1-212-713 9848

### Michael Weinstein

Associate Analyst  
michael.weinstein@ubs.com  
+1-212-713 3182

### Paul Zimbardo

Associate Analyst  
paul.zimbardo@ubs.com  
+1-212-713 1033

Highlights (US\$m)	12/12	12/13	12/14	12/15E	12/16E	12/17E	12/18E	12/19E
Revenues	2,870	2,556	2,484	1,403	1,663	1,906	2,530	2,996
EBIT (UBS)	40	(226)	(540)	(51)	563	849	1,400	2,071
Net earnings (UBS)	64	(210)	(255)	(526)	(168)	(105)	140	550
EPS (UBS, diluted) (US\$)	0.28	(0.87)	(0.95)	(1.72)	(0.53)	(0.33)	0.44	1.72
DPS (US\$)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net (debt) / cash	(279)	414	27	(222)	296	868	1,927	3,796
Profitability/valuation	12/12	12/13	12/14	12/15E	12/16E	12/17E	12/18E	12/19E
EBIT margin %	1.4	-8.9	-21.8	-3.6	33.9	44.6	55.3	69.1
ROIC (EBIT) %	1.7	(8.2)	(10.3)	(0.6)	4.0	4.3	5.5	6.7
EV/EBITDA (core) x	3.0	44.3	-27.1	4.1	1.5	1.2	0.9	0.6
P/E (UBS, diluted) x	11.0	(8.8)	(20.2)	(3.4)	(11.2)	(17.8)	13.4	3.4
Equity FCF (UBS) yield %	(68.2)	(44.6)	(17.7)	(293.8)	(392.2)	(359.9)	(309.8)	(248.9)
Net dividend yield %	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Source: Company accounts, Thomson Reuters, UBS estimates. UBS adjusted EPS is stated before goodwill-related charges and other adjustments for abnormal and economic items at the analysts' judgement. Valuations: based on an average share price that year, (E): based on a share price of US\$5.92 on 24 Dec 2015 19:38 EST

[www.ubs.com/investmentresearch](http://www.ubs.com/investmentresearch)

This report has been prepared by UBS Securities LLC. **ANALYST CERTIFICATION AND REQUIRED DISCLOSURES BEGIN ON PAGE 13.** UBS does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

## More dilution coming?

While shares have rallied on positive liquidity datapoints, we still see equity solvency as challenged. With SUNE looking to add additional debt obligations we see even further pressure on the equity layer. Additionally it appears that the latest debt offering could include some form of equity. While a warrant would not be unusual, management's disclosure (reproduced below) is unclear about form or magnitude.

*"The Company is disclosing this information as part of an ongoing financing process and intends to continue to explore the potential second lien credit facility that may include a significant amount of the Company's outstanding equity."*

## Emphasizing the Services Opportunity

While mgmt. has not emphasized this business thus far (nor provided much transparency on which MWs and margins apply), the focus of the December 24<sup>th</sup> presentation to raise debt capital was logically premised on these cash flows.

- **Margins quite high:** We continue to assume 20% margins on this business, off the roughly \$20/kW-yr we assume for a typical renewable platform. We typically assume ~\$30/kW-yr in total O&M, inclusive of property taxes, and insurances for solar projects. This would imply ~\$4/kW-yr in overall EBITDA margin for SUNE; this stands in sharp contrast to the ~\$32/kW-yr (using an average of ~7GW in 2016 as the business scales
- **Revenue acceleration:** Among the key inputs we question is the trajectory of revenues, with 1Q revenues projected at \$96 Mn vs. YE revenues at \$128 Mn, which represents a +30% change in revenue despite projections for a *tripling* in the MWs originally projected. We note the bulk of scaling expected relates to the recent acquisitions.
- **How *should* it be valued?** Services peers are quoted by mgmt. at 11.6x EV/EBITDA, with mgmt recommending valuation on its own business at a 10x multiple. Mgmt does not disclose comparable service businesses.
  - **How have we been valuing this segment?** We apply a 9x EBITDA multiple to this business at present, however off a significantly lower margin. We emphasize scaling in 2016+ appears substantially predicated on third-party contracts, likely quite vulnerable to shifts in confidence on the SUNE business model.
- **Services business trending *ahead* of guidance:** We note that while Analyst Day expectations had targeted 5GW, estimates for YE2015 are 6.4GW. That said mgmt. does not make explicit note of its 2016 MW targets.
- **Change of control a minor concern:** SUNE notes that "substantially all" service contracts lack termination rights in the event of a change of control but does not disclose further details. Information about change of control is a hot topic lately and we would believe future counterparties press for additional rights.
- **Bottom line:** While an exceptionally bullish outlook for this segment, without much discussion in recent months, we ascribe limited credibility, particularly given its unusually high revenues (and in turn margin); at best, we believe

Including PPA revenue distorts comparisons.

We emphasize *even* the 1Q16 pace (likely off the 6.4GW YE15 run-rate) would imply \$60/kW-yr in revenue, triple our historic assumption of direct O&M, and double our historic assumption of total cost structure for renewables.

The presentation for the services business provides bullish future projections but management does not reconcile with the historical performance.

investors will likely ascribe a discounted multiple vs peers to account for seemingly unsustainable revenue/margin profile of the segment. We believe the above-average revenues drive the unusually high margins to this segment.

- **What does this mean for TERP and GBL?** Given the seemingly above-market revenues allocated to the services business, this raises the latest inter-company questions following our recent governance concerns.

As mentioned, mgmt includes PPA revenue in its Services business for the December 24<sup>th</sup> presentation. The 53% 2016E gross margin drops to 41%.

**Figure 1: Services Business – Valuation - SUNE**

	1Q16	2Q16	3Q16	4Q16	2016
O&M Revenue	21	22	24	24	92
IPP PPA Revenue	34	34	34	33	134
SLB PPA Revenue	18	18	18	18	72
3rd Party O&M Revenue	23	30	41	52	146
<b>Total Revenue</b>	<b>96</b>	<b>104</b>	<b>116</b>	<b>128</b>	<b>443</b>
O&M Costs	15	16	17	17	64
IPP Costs	6	6	6	6	22
SLB Costs	12	12	12	12	47
3rd Party Costs	9	16	21	29	74
<b>Total Costs</b>	<b>41</b>	<b>49</b>	<b>55</b>	<b>63</b>	<b>208</b>
% of sales	43%	47%	47%	49%	47%
O&M Profit	6	7	7	7	28
IPP Gross Profit	28	28	28	28	112
SLB Gross Profit	6	6	6	6	24
3rd Party Gross Party	14	14	20	24	71
<b>Total Gross Profit</b>	<b>54</b>	<b>55</b>	<b>61</b>	<b>65</b>	<b>235</b>
% Margin	56%	53%	53%	51%	53%
OpEx	-3	-3	-3	-3	-12
% of sales	-3%	-3%	-3%	-2%	-3%
<b>EBITDA</b>	<b>51</b>	<b>51</b>	<b>58</b>	<b>62</b>	<b>223</b>
% Margin	53%	49%	50%	48%	50%

Source: Company presentations

**Figure 2: Services Business – Valuation off 2017 - UBSe**

Solar and Wind Servicing				
	2015 (Today)	2017	2017	Upside
Capacity (MW)	5,000	14,523	14,523	
Revenue @ \$20/kW-yr	100	290.46	290.46	
EBITDA Margin %	16%	20%	25%	
EBITDA	16	58	73	
EV/EBITDA	9.0x	9.0x	9.0x	
Implied Value	144	523	654	
Implied Value (\$/kW-yr)	3	4	5	
<b>Value to SUNE</b>	<b>\$0.41</b>	<b>\$1.48</b>	<b>\$1.85</b>	

Source: UBSe

We also include our assumptions from our UBS model for the services business, showing average MWS in 2016-2019. We project substantially lower margins than peers.

**Figure 3: Projection for Services business (UBSe)**

	FY 2015E	FY 2016E	FY 2017E	FY 2018E	FY 2019E
<b>Service Business</b>					
MWs	6,200	9,000	13,000	17,000	21,000
MW additions	2,200	2,800	4,000	4,000	4,000
Revenue (\$/kW-yr)	20	20	20	20	20
Revenue (\$ Mn)	124	180	260	340	420
Margins (%)	18%	18.0%	20.0%	22.0%	24.0%
<b>Margin (\$ Mn)</b>	<b>\$22</b>	<b>\$32</b>	<b>\$52</b>	<b>\$75</b>	<b>\$101</b>

Source: UBSe

## How Much Cash is Left?

We see the latest presentation as presenting the greatest transparency on pro-forma cash yet for the company. We see the projected ~\$268 Mn implied from SUNE's disclosures as roughly consistent with our belief that liquidity remains quite tight. Assuming a further \$266 Mn of the \$1.34 Bn is consolidated cash from TERP and GBL subsidiaries would suggest true cash liquidity at SUNE parent is *negligible* as of YE15. This would be consistent with our read into recent actions which have largely appeared to raise financing/proceeds on a short-term basis to address forthcoming obligations.

- FirstWind earnout: Notably 4Q cash burn assumes \$215 Mn of payment is made by SUNE, rather than any other subsidiaries (TERP). Notably, SUNE is also assuming a further FirstWind payout of \$125 Mn in 1Q16; timing could potentially be delayed to later in the year if similar to the initial payment structure in 2015.
- Equity investments in 4Q could further obfuscate factor: While we have allocated \$254 and \$283 Mn in cash equity investments for the purposes of this cash walk, there could be some overlap with the projected FCF 4Q cash burn of -\$535 Mn below.

**Figure 4: SUNE Project Cash Disclosures (incl. consolidated TERP & GBL cash)**

<b>SUNE Projected Cash Disclosures</b>	
1,340	Cash and Cash Committed For Construction of Projects (9/30)
(254)	Solar Cash Equity Investments
(283)	Wind Cash Equity Investments
(535)	FCF for 4Q Cashburn
<b>268</b>	<b>UBSe Projected as of 12/31/2015 (from Disclosures)</b>

Source: Company Filings and UBS Estimates

## Changes in Working Capital in 2016: Still Drawing Down

Among the key liquidity datapoints in the projections is the drawdown of Net PP&E in 1Q and 2Q, as investment in projects ramp up to hit the targeted 3.5GW. We emphasize the quarterly use in cash remains biased towards 1H, suggesting we expect to see either an acceleration in financing activities to fund cash burn or a reduction in guidance.

**Figure 5: 2016 Projected Working Capital**

<b>2016 Projected Working Capital</b>	
(259)	Changes in W/C
(428)	Changes in Net PP&E
298	Changes in pre-construction, construction, and term debt
<b>(389)</b>	<b>UBSe Projected as of 12/31/2015 (from Disclosures)</b>

Source: Company Filings and UBS Estimates

## Keeping Guidance Intact (for now)

While we continue to expect a slowing of guidance, mgmt. did not formally reduce its guidance in the enclosed deck. *We continue to expect a scaling back of capex and MW deployment in 2016.*

## Margins are reflected near midpoint

With SUNE having historically guided towards 15-20% margins, 2016 projections reflect an average of 17% (with direct sales reflecting the lower end of the range at 16.1% and Warehouse sales at 17.1%). The key question is how firm these margins to the warehouse structure are given the ~10% upfront nature of these deals. We include the full table of disclosures below.

## Costs still at \$600 Mn ... can more come out?

Following news headlines of further scaling back in India and Japan, we wouldn't be surprised to see this figure reduced yet further, particularly in conjunction with any reduction in DevCo gross margin expectations.

## Can the materials business recover?

Among the 'moving pieces' we have not accounted for in our estimates, but appears to oscillate considerably is SUNE's material business. While the company projects an -\$88 Mn margin loss in 4Q, we see the \$121 Mn in positive margin as uncertain give the relatively depressed value of poly prices.

**Figure 6: Cash based EBITDA and EBITDA operating metrics**

Total MW Completed	4Q15	1Q16	2Q16	3Q16	4Q16	FY2016		<u>Implied \$ / W</u>	4Q15	1Q16	2Q16	3Q16	4Q16	FY2016
Direct Sales	74	106	79	542	174	900		Direct Sales	\$1.68	\$2.18	\$2.18	\$2.18	\$2.18	\$2.18
TERP	44	15	15	0	0	30		TERP	\$2.97	\$2.77	\$2.77			\$2.77
GLBL	115	172	252	0	0	424		GLBL	\$1.64	\$1.58	\$1.58			\$1.58
Warehouse	218	100	473	489	1084	2145		Warehouse	\$1.76	\$2.04	\$2.04	\$2.04	\$2.04	\$2.04
<b>Total</b>	<b>450</b>	<b>393</b>	<b>819</b>	<b>1031</b>	<b>1258</b>	<b>3500</b>		Average for projects	\$1.83	\$1.90	\$1.93	\$2.11	\$2.06	\$2.03
<b>Revenue</b>								<u>QoQ growth</u>						
Direct Sales	\$124	\$230	\$172	\$1,180	\$378	\$1,959		Direct Sales		85%	-25%	588%	-68%	
TERP	\$131	\$42	\$42	\$0	\$0	\$84		TERP		-68%	0%	-100%		
GLBL	\$189	\$272	\$399	\$0	\$0	\$671		GLBL		44%	46%	-100%		
Warehouse	\$383	\$204	\$966	\$998	\$2,215	\$4,383		Warehouse		-47%	373%	3%	122%	
<b>Total Projects</b>	<b>\$826</b>	<b>\$748</b>	<b>\$1,578</b>	<b>\$2,178</b>	<b>\$2,593</b>	<b>\$7,097</b>		<b>Total Projects</b>		<b>-9%</b>	<b>111%</b>	<b>38%</b>	<b>19%</b>	
IPP, SLB & Services	\$84	\$96	\$104	\$116	\$128	\$443		IPP & Services		13%	8%	12%	10%	
Solar Materials	\$102	\$100	\$79	\$64	\$92	\$336		Solar Materials		-2%	-21%	-19%	44%	
<b>Total</b>	<b>\$1,012</b>	<b>\$944</b>	<b>\$1,761</b>	<b>\$2,359</b>	<b>\$2,813</b>	<b>\$7,876</b>		<b>Total</b>						
<b>Gross Margin</b>								<u>GM as % of sales</u>						
Direct Sales	\$13	\$37	\$28	\$190	\$61	\$315		Direct Sales	10%	16%	16%	16%	16%	16%
TERP	\$20	\$5	\$5	\$0	\$0	\$11		TERP	15%	12%	12%			13%
GLBL	\$38	\$60	\$88	\$0	\$0	\$149		GLBL	20%	22%	22%			22%
Warehouse	\$44	\$35	\$165	\$171	\$379	\$751		Warehouse	11%	17%	17%	17%	17%	17%
<b>Total Projects</b>	<b>\$115</b>	<b>\$138</b>	<b>\$287</b>	<b>\$361</b>	<b>\$440</b>	<b>\$1,225</b>		<b>Total Projects</b>	<b>14%</b>	<b>18%</b>	<b>18%</b>	<b>17%</b>	<b>17%</b>	<b>17%</b>
IPP, SLB & Services	\$44	\$54	\$55	\$61	\$65	\$235		IPP, SLB & Services	52%	56%	53%	53%	51%	53%
Solar Materials	(\$88)	\$100	\$72	(\$105)	\$54	\$121		Solar Materials	-86%	100%	91%	-164%	59%	36%
<b>Total Gross Margin</b>	<b>\$71</b>	<b>\$292</b>	<b>\$413</b>	<b>\$317</b>	<b>\$559</b>	<b>\$1,581</b>		<b>Total GM</b>	<b>7%</b>	<b>31%</b>	<b>23%</b>	<b>13%</b>	<b>20%</b>	<b>20%</b>
Operating expenses	\$190	\$150	\$150	\$150	\$150	\$600		Opex as % of sales	19%	16%	9%	6%	5%	8%
D&A	\$49	\$49	\$49	\$50	\$50	\$198		D&A as % of sales	5%	5%	3%	2%	2%	3%
<b>EBIT</b>	<b>(\$169)</b>	<b>\$93</b>	<b>\$214</b>	<b>\$117</b>	<b>\$359</b>	<b>\$783</b>		<b>EBIT margin</b>	<b>-17%</b>	<b>10%</b>	<b>12%</b>	<b>5%</b>	<b>13%</b>	<b>10%</b>
D&A	\$49	\$49	\$49	\$50	\$50	\$198								
Stock Comp & Other Non Cash	\$1	\$19	\$19	\$19	\$19	\$77								
Dividends & IDRs	\$23	\$32	\$32	\$32	\$32	\$128								
<b>Adjusted EBITDA</b>	<b>(\$95)</b>	<b>\$193</b>	<b>\$314</b>	<b>\$218</b>	<b>\$460</b>	<b>\$1,186</b>		<b>EBITDA margin</b>	<b>-9%</b>	<b>20%</b>	<b>18%</b>	<b>9%</b>	<b>16%</b>	<b>15%</b>

Source: Company presentation

## The Full Disclosure

We reproduce management's projected full cash flow liquidity through 4Q16.

**Figure 7: Projected Cash Flow – 2016**

CFO	4Q15	1Q16	2Q16	3Q16	4Q16	FY2016
Adjusted EBITDA(a)	(\$95)	\$193	\$314	\$218	\$460	\$1,186
Plus / (Less): Cash interest expense	(\$86)	(\$85)	(\$99)	(\$83)	(\$96)	(\$363)
Plus / (Less): Cash taxes(b)	\$0	\$0	\$0	\$0	\$0	\$0
Plus / (Less): Change in Working Capital	(\$112)	(\$112)	(\$27)	\$44	(\$164)	(\$259)
Plus / (Less): Change in PP&E	(\$131)	(\$676)	(\$536)	\$198	\$585	(\$428)
Plus / (Less): Change in pre-construction, construction, and term debt	\$89	\$462	\$212	\$66	(\$442)	\$298
Plus / (Less): Other(c)	\$0	(\$25)	\$42	(\$22)	(\$5)	(\$10)
<b>Total CFO</b>	<b>(\$335)</b>	<b>(\$243)</b>	<b>(\$94)</b>	<b>\$422</b>	<b>\$340</b>	<b>\$424</b>
<b>CFI</b>						
Sale of 425MW to GLBL and margin offset	\$231	(\$58)	(\$58)	(\$58)	(\$58)	(\$231)
Vivint acquisition	\$0	(\$1,058)	\$0	\$0	\$0	(\$1,058)
First Wind Earnout	(\$215)	(\$125)	\$0	\$0	\$0	(\$125)
Proceeds from asset sales	\$27	\$64	\$143	\$63	\$0	\$270
<b>Total CFI</b>	<b>\$43</b>	<b>(\$1,176)</b>	<b>\$85</b>	<b>\$5</b>	<b>(\$58)</b>	<b>(\$1,144)</b>
<b>CFF</b>						
Equity to Vivint sellers	\$0	\$456	\$0	\$0	\$0	\$456
New Vivint convertible bonds	\$0	\$350	\$0	\$0	\$0	\$350
New Vivint Term Loan	\$0	\$258	(\$95)	(\$122)	(\$40)	\$0
New Vivint Blackstone Loan	\$0	\$244	(\$6)	(\$6)	(\$6)	\$225
Existing Margin Loan repayment	(\$399)	\$0	\$0	\$0	\$0	\$0
Release of restricted cash	\$147	\$0	\$0	\$0	\$0	\$0
Financing leaseback obligations	(\$4)	(\$4)	(\$4)	(\$4)	(\$4)	(\$15)
Other financing	\$12	\$0	\$0	\$0	\$0	\$0
<b>Total CFF</b>	<b>(\$244)</b>	<b>\$1,304</b>	<b>(\$105)</b>	<b>(\$132)</b>	<b>(\$50)</b>	<b>\$1,016</b>
<b>Delta in cash</b>	<b>(\$535)</b>	<b>(\$115)</b>	<b>(\$114)</b>	<b>\$294</b>	<b>\$232</b>	<b>\$296</b>
<b>Beginning cash, including cash committed for construction projects</b>	<b>\$1,340</b>	<b>\$805</b>	<b>\$689</b>	<b>\$575</b>	<b>\$870</b>	<b>\$805</b>
<b>Delta in cash</b>	<b>(\$535)</b>	<b>(\$115)</b>	<b>(\$114)</b>	<b>\$294</b>	<b>\$232</b>	<b>\$296</b>
<b>Ending cash, including cash committed for construction projects</b>	<b>\$805</b>	<b>\$689</b>	<b>\$575</b>	<b>\$870</b>	<b>\$1,101</b>	<b>\$1,101</b>

Source: Company presentation

## What are the major moving pieces?

We also reproduce the full cash flow walk from 3Q15 (9/30) through 4Q16.

- The below does *not* reflect an additional \$155 Mn of collateral that would be released upon repayment of the \$300 Mn term loan. Reasoning for not including however is unclear per mgmt.

**Figure 8: Aggregate cash – 3Q15 – 4Q16**

<b>Beginning Cash - 3Q15</b>	<b>\$1,340</b>
CFO	\$642
Debt raised	\$388
Capex	(\$559)
Wrking Capital	(\$370)
<b>Total CFO</b>	<b>\$101</b>
CFI	
425 MW Sold to GLBL	\$231
GLBL margin offset	(\$231)
Sale of development assets	\$297
First Wind Earnout	(\$340)
<b>Total Investment ex Acquisition</b>	<b>(\$43)</b>
Vivint	
Equity Issuance	\$456
Issuance of Convertible notes	\$350
Issuance of term loan	\$300
Issuance of Blackstone loan	\$250
Acquisition	(\$1,058)
<b>Total Acquisition</b>	<b>\$298</b>
<b>Total CFI</b>	<b>\$255</b>
CFI	
Vivint	
Blackstone Loan repayment	(\$25)
Term Loan Repayment	(\$300)
Margin Loan repayment	(\$399)
Release of restricted cash	\$147
Other	(\$17)
<b>Total CFF</b>	<b>(\$594)</b>
<b>Ending Cash - 4Q16</b>	<b>\$1,102</b>

Source: Company presentation


## Key Financing Assumptions

We note the 2016 CFF profile assumes the repayment of the \$300 Mn term loan associated with the Vivint acquisition, which we had assumed was to be ratably paid down as a function of margins generated by the Vivint acquisition (amortizing over a ~couple years). Further, we note the 2016 GS term loan repayment is *not* reflected in the YoY walk despite its maturity in August, 2016. However, this paydown would appear fungible with the repayment of the VSLR term loan.

## When will projects come to fruition?

Mgmt reflects a project completion profile, showing the % completion of projects and associated \$ Mn investments. With the largest portion in the 30-50% range, we think much of this is contemplated for late 2016 consistent with the original ITC expiration timeline.

**Figure 9: Equity invested into projects vs status of project completions**



Source: Company presentation

## Contrasting against mgmt's updated self-valuation?

SUNE mgmt. provided an updated view on how it views the SOP value proposition for shares.

- **Services:** Notably higher is \$2.2 Bn in value for the Services business (prominently featured at the top of its latest SOP table). This would imply \$7/sh vs. our \$1.50 we reflect today. As mentioned, management's services business as presented seemingly includes the cash flows generated by operating assets which we value separately (~\$1.50/sh). The core question is how to treat and what the source of the IPP PPA and SLB PPA revenues now recognized in this segment are, which had previously not been included in this segment.
- **'Other' segment:** Mgmt is also emphasizing the value proposition of its three principal 'other' segments reflecting a total of \$490 Mn. We had previously removed the value from its poly business as poly prices fell in 2H15, net of debt at the plant.
  - **SMP Value** = \$225 Mn based on total \$408 Mn equity value, implying ~\$0.60/sh.
  - **Mosaix and MEMC Pasadena** = \$265 Mn in book value. While mgmt. discloses strong interest from manufacturing companies globally to license its technology, we hold off on ascribing any value.
- **Pipeline and Backlog value:** Mgmt estimates implied pipeline/backlog value for the Solar business at \$3 Bn+, on its 6GW total, implying \$0.50/W. We note with fully developed projects targeted to monetize at \$0.35/W, this

assumptions appears robust. With 1.9GW in Wind Pipeline/Backlog, mgmt. estimates value here at \$2Bn+, suggesting north of \$1.0/W in value.

While we appreciate a need to ascribe value for the overall devco platform, we would apply a discount to committed backlog projects (eg- 50% of \$0.35/W) should the business liquidate its platform rather than develop assets. Overall implied backlog and pipeline are estimated at \$5 Bn or ~\$15/sh, vs. the ~\$9/sh we already apply in our full Devco value (using a 5x multiple off '16 EBITDA).

## Reflecting Updated Cash Walk Assumptions in SOP

We include an updated approach to reflecting SUNE's cash balance, netting out not just TERP and GLBL cash balances but also assets held for sale as well as cash commitments already to solar and wind assets.

<b>Pro-Forma SUNE Cash Walk</b>	<b>3Q15</b>
SUNE total cash (from 3Q presentation)	\$ 1,380
<i>Assets Held for Sale</i>	<i>(40)</i>
<i>TERP restricted cash (on subsidiary b/s)</i>	<i>(90)</i>
<i>GLBL restricted cash (on subsidiary b/s)</i>	<i>(176)</i>
<i>Cash Committed to Solar/Wind Assets</i>	<i>(537)</i>
<b>3Q15 Pro-Forma Net Cash</b>	<b>\$ 537</b>

Source: Company data, UBSe

**Forecast returns**

---

Forecast price appreciation	-66.2%
Forecast dividend yield	0.0%
Forecast stock return	-66.2%
Market return assumption	6.0%
Forecast excess return	-72.2%

---

**Statement of Risk**

Risks to SunEdison include but are not limited to: liquidity and failure to meet liabilities and other obligations as due, potential failure to close the pending Vivint Solar and other contemplated M&A transactions, inability to transact with its YieldCo entities in an accretive fashion, inability to transact with third parties in an accretive fashion, increasing cost structure and competition pressuring realized margins, unfavorable international, federal, state, or local legislation/regulation, natural disasters, increased competition for project development opportunities, adverse changes to tax subsidies for solar and wind generation, unfavorable weather (wind and solar resource generation), below-average customer demand. SunEdison's expansion plans are also driven by expected cost reductions in renewable energy system equipment. Additionally, adoption of renewable energy generation is associated with the costs of incumbent generation sources and will be heavily impacted by any large swing in the costs of these energy sources. Swings in value can be driven by shifts in TERP shares and corresponding ability to realize Incentive Distribution Rights (IDRs). Moreover, developer margins are highly cyclical off a large fixed operating cost structure.

## Required Disclosures

This report has been prepared by UBS Securities LLC, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

For information on the ways in which UBS manages conflicts and maintains independence of its research product; historical performance information; and certain additional disclosures concerning UBS research recommendations, please visit [www.ubs.com/disclosures](http://www.ubs.com/disclosures). The figures contained in performance charts refer to the past; past performance is not a reliable indicator of future results. Additional information will be made available upon request. UBS Securities Co. Limited is licensed to conduct securities investment consultancy businesses by the China Securities Regulatory Commission.

**Analyst Certification:** Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner, including with respect to UBS, and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

### UBS Investment Research: Global Equity Rating Definitions

12-Month Rating	Definition	Coverage <sup>1</sup>	IB Services <sup>2</sup>
Buy	FSR is > 6% above the MRA.	49%	33%
Neutral	FSR is between -6% and 6% of the MRA.	40%	26%
Sell	FSR is > 6% below the MRA.	12%	18%
Short-Term Rating	Definition	Coverage <sup>3</sup>	IB Services <sup>4</sup>
Buy	Stock price expected to rise within three months from the time the rating was assigned because of a specific catalyst or event.	less than 1%	less than 1%
Sell	Stock price expected to fall within three months from the time the rating was assigned because of a specific catalyst or event.	less than 1%	less than 1%

Source: UBS. Rating allocations are as of 30 September 2015.

1:Percentage of companies under coverage globally within the 12-month rating category. 2:Percentage of companies within the 12-month rating category for which investment banking (IB) services were provided within the past 12 months.

3:Percentage of companies under coverage globally within the Short-Term rating category. 4:Percentage of companies within the Short-Term rating category for which investment banking (IB) services were provided within the past 12 months.

**KEY DEFINITIONS:** **Forecast Stock Return (FSR)** is defined as expected percentage price appreciation plus gross dividend yield over the next 12 months. **Market Return Assumption (MRA)** is defined as the one-year local market interest rate plus 5% (a proxy for, and not a forecast of, the equity risk premium). **Under Review (UR)** Stocks may be flagged as UR by the analyst, indicating that the stock's price target and/or rating are subject to possible change in the near term, usually in response to an event that may affect the investment case or valuation. **Short-Term Ratings** reflect the expected near-term (up to three months) performance of the stock and do not reflect any change in the fundamental view or investment case. **Equity Price Targets** have an investment horizon of 12 months.

**EXCEPTIONS AND SPECIAL CASES:** **UK and European Investment Fund ratings and definitions are:** **Buy:** Positive on factors such as structure, management, performance record, discount; **Neutral:** Neutral on factors such as structure, management, performance record, discount; **Sell:** Negative on factors such as structure, management, performance record, discount. **Core Banding Exceptions (CBE):** Exceptions to the standard +/-6% bands may be granted by the Investment Review Committee (IRC). Factors considered by the IRC include the stock's volatility and the credit spread of the respective company's debt. As a result, stocks deemed to be very high or low risk may be subject to higher or lower bands as they relate to the rating. When such exceptions apply, they will be identified in the Company Disclosures table in the relevant research piece.

Research analysts contributing to this report who are employed by any non-US affiliate of UBS Securities LLC are not registered/qualified as research analysts with FINRA. Such analysts may not be associated persons of UBS Securities LLC and therefore are not subject to the FINRA restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account. The name of each affiliate and analyst employed by that affiliate contributing to this report, if any, follows.

**UBS Securities LLC:** Julien Dumoulin-Smith; Michael Weinstein; Paul Zimbardo.

## Company Disclosures

Company Name	Reuters	12-month rating	Short-term rating	Price	Price date
<b>SunEdison Inc.</b> <sup>13, 16</sup>	SUNE.N	Sell	N/A	US\$5.92	24 Dec 2015
<b>TerraForm Power, Inc.</b> <sup>2, 4, 5, 6, 16</sup>	TERP.O	Sell	N/A	US\$12.15	24 Dec 2015
<b>Vivint Solar Inc</b> <sup>16</sup>	VSLR.N	Not Rated	N/A	US\$9.82	24 Dec 2015


Source: UBS. All prices as of local market close.

Ratings in this table are the most current published ratings prior to this report. They may be more recent than the stock pricing date

2. UBS AG, its affiliates or subsidiaries has acted as manager/co-manager in the underwriting or placement of securities of this company/entity or one of its affiliates within the past 12 months.
4. Within the past 12 months, UBS AG, its affiliates or subsidiaries has received compensation for investment banking services from this company/entity or one of its affiliates.
5. UBS AG, its affiliates or subsidiaries expect to receive or intend to seek compensation for investment banking services from this company/entity within the next three months.
6. This company/entity is, or within the past 12 months has been, a client of UBS Securities LLC, and investment banking services are being, or have been, provided.
13. UBS AG, its affiliates or subsidiaries beneficially owned 1% or more of a class of this company's common equity securities as of last month's end (or the prior month's end if this report is dated less than 10 days after the most recent month's end).
16. UBS Securities LLC makes a market in the securities and/or ADRs of this company.


Unless otherwise indicated, please refer to the Valuation and Risk sections within the body of this report.

### SunEdison Inc. (US\$)




Source: UBS; as of 24 Dec 2015

## TerraForm Power, Inc. (US\$)



Source: UBS; as of 24 Dec 2015

## Vivint Solar Inc (US\$)



Source: UBS; as of 24 Dec 2015

## Global Disclaimer

This document has been prepared by UBS Securities LLC, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

Global Research is provided to our clients through UBS Neo, the UBS Client Portal and UBS.com (each a "System"). It may also be made available through third party vendors and distributed by UBS and/or third parties via e-mail or alternative electronic means. The level and types of services provided by Global Research to a client may vary depending upon various factors such as a client's individual preferences as to the frequency and manner of receiving communications, a client's risk profile and investment focus and perspective (e.g. market wide, sector specific, long-term, short-term, etc.), the size and scope of the overall client relationship with UBS and legal and regulatory constraints.

When you receive Global Research through a System, your access and/or use of such Global Research is subject to this Global Research Disclaimer and to the terms of use governing the applicable System.

When you receive Global Research via a third party vendor, e-mail or other electronic means, your use shall be subject to this Global Research Disclaimer and to UBS's Terms of Use/Disclaimer (<http://www.ubs.com/global/en/legalinfo2/disclaimer.html>). By accessing and/or using Global Research in this manner, you are indicating that you have read and agree to be bound by our Terms of Use/Disclaimer. In addition, you consent to UBS processing your personal data and using cookies in accordance with our Privacy Statement (<http://www.ubs.com/global/en/legalinfo2/privacy.html>) and cookie notice (<http://www.ubs.com/global/en/homepage/cookies/cookie-management.html>).

**If you receive Global Research, whether through a System or by any other means, you agree that you shall not copy, revise, amend, create a derivative work, transfer to any third party, or in any way commercially exploit any UBS research provided via Global Research or otherwise, and that you shall not extract data from any research or estimates provided to you via Global Research or otherwise, without the prior written consent of UBS.**

For access to all available Global Research on UBS Neo and the Client Portal, please contact your UBS sales representative.

This document is for distribution only as may be permitted by law. It is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject UBS to any registration or licensing requirement within such jurisdiction. It is published solely for information purposes; it is not an advertisement nor is it a solicitation or an offer to buy or sell any financial instruments or to participate in any particular trading strategy. No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained in this document ('the Information'), except with respect to Information concerning UBS. The Information is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. UBS does not undertake to update or keep current the Information. Any opinions expressed in this document may change without notice and may differ or be contrary to opinions expressed by other business areas or groups of UBS. Any statements contained in this report attributed to a third party represent UBS's interpretation of the data, information and/or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party.

Nothing in this document constitutes a representation that any investment strategy or recommendation is suitable or appropriate to an investor's individual circumstances or otherwise constitutes a personal recommendation. Investments involve risks, and investors should exercise prudence and their own judgement in making their investment decisions. The financial instruments described in the document may not be eligible for sale in all jurisdictions or to certain categories of investors. Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates or other market conditions. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument referred to in the document. For investment advice, trade execution or other enquiries, clients should contact their local sales representative.

The value of any investment or income may go down as well as up, and investors may not get back the full (or any) amount invested. Past performance is not necessarily a guide to future performance. Neither UBS nor any of its directors, employees or agents accepts any liability for any loss (including investment loss) or damage arising out of the use of all or any of the Information.

Any prices stated in this document are for information purposes only and do not represent valuations for individual securities or other financial instruments. There is no representation that any transaction can or could have been effected at those prices, and any prices do not necessarily reflect UBS's internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions by UBS or any other source may yield substantially different results.

This document and the Information are produced by UBS as part of its research function and are provided to you solely for general background information. UBS has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient. In no circumstances may this document or any of the Information be used for any of the following purposes:

- (i) valuation or accounting purposes;
- (ii) to determine the amounts due or payable, the price or the value of any financial instrument or financial contract; or
- (iii) to measure the performance of any financial instrument.

By receiving this document and the Information you will be deemed to represent and warrant to UBS that you will not use this document or any of the Information for any of the above purposes or otherwise rely upon this document or any of the Information.

Research will initiate, update and cease coverage solely at the discretion of UBS Investment Bank Research Management. The analysis contained in this document is based on numerous assumptions. Different assumptions could result in materially different results. The analyst(s) responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting market information. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS into other areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this document is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues; however, compensation may relate to the revenues of UBS Investment Bank as a whole, of which investment banking, sales and trading are a part.

For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC) acts as a market maker or liquidity provider (in accordance with the interpretation of these terms in the UK) in the financial instruments of the issuer save that where the activity of liquidity provider is carried out in accordance with the definition given to it by the laws and regulations of any other EU jurisdictions, such information is separately disclosed in this document. For financial instruments admitted to trading on a non-EU regulated market: UBS may act as a market maker save that where this activity is carried out in the US in accordance with the definition given to it by the relevant laws and regulations, such activity will be specifically disclosed in this document. UBS may have issued a warrant the value of which is based on one or more of the financial instruments referred to in the document. UBS and its affiliates and employees may have long or short positions, trade as principal and buy and sell in instruments or derivatives identified herein; such transactions or positions may be inconsistent with the opinions expressed in this document.

**United Kingdom and the rest of Europe:** Except as otherwise specified herein, this material is distributed by UBS Limited to persons who are eligible counterparties or professional clients. UBS Limited is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. **France:** Prepared by UBS Limited and distributed by UBS Limited and UBS Securities France S.A. UBS Securities France S.A. is regulated by the ACPR (Autorité de Contrôle Prudentiel et de Résolution) and the Autorité des Marchés Financiers (AMF). Where an analyst of UBS Securities France S.A. has contributed to this document, the document is also deemed to have been prepared by UBS Securities France S.A. **Germany:** Prepared by UBS Limited and distributed by UBS Limited and UBS Deutschland AG. UBS Deutschland AG is regulated by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin). **Spain:** Prepared by UBS Limited and distributed by UBS Limited and UBS Securities España SV, SA. UBS Securities España SV, SA is regulated by the Comisión Nacional del Mercado de Valores (CNMV). **Turkey:** Distributed by UBS Limited. No information in this document is provided for the purpose of offering, marketing and sale by any means of any capital market instruments and services in the Republic of Turkey. Therefore, this document may not be considered as an offer made or to be made to residents of the Republic of Turkey. UBS AG is not licensed by the Turkish Capital Market Board under the provisions of the Capital Market Law (Law No. 6362). Accordingly, neither this document nor any other offering material related to the instruments/services may be utilized in connection with providing any capital market services to persons within the Republic of Turkey without the prior approval of the Capital Market Board. However, according to article 15 (d) (ii) of the Decree No. 32, there is no restriction on the purchase or sale of the securities abroad by residents of the Republic of Turkey. **Poland:** Distributed by UBS Limited (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce regulated by the Polish Financial Supervision Authority. Where an analyst of UBS Limited (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce has contributed to this

document, the document is also deemed to have been prepared by UBS Limited (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce. **Russia:** Prepared and distributed by UBS Bank (OOO). **Switzerland:** Distributed by UBS AG to persons who are institutional investors only. UBS AG is regulated by the Swiss Financial Market Supervisory Authority (FINMA). **Italy:** Prepared by UBS Limited and distributed by UBS Limited and UBS Italia Sim S.p.A. UBS Italia Sim S.p.A. is regulated by the Bank of Italy and by the Commissione Nazionale per le Società e la Borsa (CONSOB). Where an analyst of UBS Italia Sim S.p.A. has contributed to this document, the document is also deemed to have been prepared by UBS Italia Sim S.p.A. **South Africa:** Distributed by UBS South Africa (Pty) Limited (Registration No. 1995/011140/07), an authorised user of the JSE and an authorised Financial Services Provider (FSP 7328). **Israel:** This material is distributed by UBS Limited. UBS Limited is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. UBS Securities Israel Ltd is a licensed Investment Marketer that is supervised by the Israel Securities Authority (ISA). UBS Limited and its affiliates incorporated outside Israel are not licensed under the Israeli Advisory Law. UBS Limited is not covered by insurance as required from a licensee under the Israeli Advisory Law. UBS may engage among others in issuance of Financial Assets or in distribution of Financial Assets of other issuers for fees or other benefits. UBS Limited and its affiliates may prefer various Financial Assets to which they have or may have Affiliation (as such term is defined under the Israeli Advisory Law). Nothing in this Material should be considered as investment advice under the Israeli Advisory Law. This Material is being issued only to and/or is directed only at persons who are Eligible Clients within the meaning of the Israeli Advisory Law, and this material must not be relied on or acted upon by any other persons. **Saudi Arabia:** This document has been issued by UBS AG (and/or any of its subsidiaries, branches or affiliates), a public company limited by shares, incorporated in Switzerland with its registered offices at Aeschenvorstadt 1, CH-4051 Basel and Bahnhofstrasse 45, CH-8001 Zurich. This publication has been approved by UBS Saudi Arabia (a subsidiary of UBS AG), a Saudi closed joint stock company incorporated in the Kingdom of Saudi Arabia under commercial register number 1010257812 having its registered office at Tatweer Towers, P.O. Box 75724, Riyadh 11588, Kingdom of Saudi Arabia. UBS Saudi Arabia is authorized and regulated by the Capital Market Authority to conduct securities business under license number 08113-37. **Dubai:** The information distributed by UBS AG Dubai Branch is intended for Professional Clients only and is not for further distribution within the United Arab Emirates. **United States:** Distributed to US persons by either UBS Securities LLC or by UBS Financial Services Inc., subsidiaries of UBS AG; or by a group, subsidiary or affiliate of UBS AG that is not registered as a US broker-dealer (a 'non-US affiliate') to major US institutional investors only. UBS Securities LLC or UBS Financial Services Inc. accepts responsibility for the content of a document prepared by another non-US affiliate when distributed to US persons by UBS Securities LLC or UBS Financial Services Inc. All transactions by a US person in the securities mentioned in this document must be effected through UBS Securities LLC or UBS Financial Services Inc., and not through a non-US affiliate. UBS Securities LLC is not acting as a municipal advisor to any municipal entity or obligated person within the meaning of Section 15B of the Securities Exchange Act (the "Municipal Advisor Rule"), and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of the Municipal Advisor Rule. **Canada:** Distributed by UBS Securities Canada Inc., a registered investment dealer in Canada and a Member-Canadian Investor Protection Fund, or by another affiliate of UBS AG that is registered to conduct business in Canada or is otherwise exempt from registration. **Brazil:** Except as otherwise specified herein, this material is prepared by UBS Brasil CCTVM S.A. to persons who are eligible investors residing in Brazil, which are considered to be: (i) financial institutions, (ii) insurance firms and investment capital companies, (iii) supplementary pension entities, (iv) entities that hold financial investments higher than R\$300,000.00 and that confirm the status of qualified investors in written, (v) investment funds, (vi) securities portfolio managers and securities consultants duly authorized by Comissão de Valores Mobiliários (CVM), regarding their own investments, and (vii) social security systems created by the Federal Government, States, and Municipalities. **Hong Kong:** Distributed by UBS Securities Asia Limited and/or UBS AG, Hong Kong Branch. **Singapore:** Distributed by UBS Securities Pte. Ltd. [MCI (P) 018/09/2015 and Co. Reg. No.: 198500648C] or UBS AG, Singapore Branch. Please contact UBS Securities Pte. Ltd., an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110); or UBS AG, Singapore Branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Banking Act (Cap. 19) regulated by the Monetary Authority of Singapore, in respect of any matters arising from, or in connection with, the analysis or document. The recipients of this document represent and warrant that they are accredited and institutional investors as defined in the Securities and Futures Act (Cap. 289). **Japan:** Distributed by UBS Securities Japan Co., Ltd. to professional investors (except as otherwise permitted). Where this document has been prepared by UBS Securities Japan Co., Ltd., UBS Securities Japan Co., Ltd. is the author, publisher and distributor of the document. Distributed by UBS AG, Tokyo Branch to Professional Investors (except as otherwise permitted) in relation to foreign exchange and other banking businesses when relevant. **Australia:** Clients of UBS AG: Distributed by UBS AG (Holder of Australian Financial Services License No. 231087). Clients of UBS Securities Australia Ltd: Distributed by UBS Securities Australia Ltd (Holder of Australian Financial Services License No. 231098). Clients of UBS Wealth Management Australia Ltd: Distributed by UBS Wealth Management Australia Ltd (Holder of Australian Financial Services License No. 231127). This Document contains general information and/or general advice only and does not constitute personal financial product advice. As such, the Information in this document has been prepared without taking into account any investor's objectives, financial situation or needs, and investors should, before acting on the Information, consider the appropriateness of the Information, having regard to their objectives, financial situation and needs. If the Information contained in this document relates to the acquisition, or potential acquisition of a particular financial product by a 'Retail' client as defined by section 761G of the Corporations Act 2001 where a Product Disclosure Statement would be required, the retail client should obtain and consider the Product Disclosure Statement relating to the product before making any decision about whether to acquire the product. The UBS Securities Australia Limited Financial Services Guide is available at: [www.ubs.com/ecs-research-fsg](http://www.ubs.com/ecs-research-fsg). **New Zealand:** Distributed by UBS New Zealand Ltd. The information and recommendations in this publication are provided for general information purposes only. To the extent that any such information or recommendations constitute financial advice, they do not take into account any person's particular financial situation or goals. We recommend that recipients seek advice specific to their circumstances from their financial advisor. **Korea:** Distributed in Korea by UBS Securities Pte. Ltd., Seoul Branch. This document may have been edited or contributed to from time to time by affiliates of UBS Securities Pte. Ltd., Seoul Branch. **Malaysia:** This material is authorized to be distributed in Malaysia by UBS Securities Malaysia Sdn. Bhd (Capital Markets Services License No.: CMSL/A0063/2007). This material is intended for professional/institutional clients only and not for distribution to any retail clients. **India:** Prepared by UBS Securities India Private Ltd. (Corporate Identity Number U67120MH1996PTC097299) 2/F, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai (India) 400051. Phone: +912261556000. It provides brokerage services bearing SEBI Registration Numbers: NSE (Capital Market Segment): INB230951431, NSE (F&O Segment) INF230951431, NSE (Currency Derivatives Segment) INE230951431, BSE (Capital Market Segment) INB010951437; merchant banking services bearing SEBI Registration Number: INM000010809 and Research Analyst services bearing SEBI Registration Number: INH000001204. UBS AG, its affiliates or subsidiaries may have debt holdings or positions in the subject Indian company/companies. Within the past 12 months, UBS AG, its affiliates or subsidiaries may have received compensation for non-investment banking securities-related services and/or non-securities services from the subject Indian company/companies. The subject company/companies may have been a client/clients of UBS AG, its affiliates or subsidiaries during the 12 months preceding the date of distribution of the research report with respect to investment banking and/or non-investment banking securities-related services and/or non-securities services. With regard to information on associates, please refer to the Annual Report at: [http://www.ubs.com/global/en/about\\_ubs/investor\\_relations/annualreporting.html](http://www.ubs.com/global/en/about_ubs/investor_relations/annualreporting.html)

The disclosures contained in research documents produced by UBS Limited shall be governed by and construed in accordance with English law.

UBS specifically prohibits the redistribution of this document in whole or in part without the written permission of UBS and UBS accepts no liability whatsoever for the actions of third parties in this respect. Images may depict objects or elements that are protected by third party copyright, trademarks and other intellectual property rights. © UBS 2015. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.

